Prognostic value of the baseline circulating T cell receptor β chain diversity in advanced lung cancer
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC..
An indicator for systemic evaluation of the adaptive immune status is lacking. Peripheral blood is important in antitumour immunity, and the T-cell receptor (TCR) repertoire diversity is key for effective immunity. This study aimed to investigate changes in the circulating T cell receptor β chain (TCRB) diversity during the first few (1 ~ 4) treatment cycles and its clinical value in patients with advanced lung cancer. TCRB-enriched sequencing data combined with transcriptomic RNA sequencing data of peripheral blood leukocytes were obtained from 72 patients with advanced lung cancer before and after targeted therapy or chemotherapy. Changes in the circulating TCRB diversity during treatment and the relationship of the baseline circulating TCRB diversity with prognosis and therapeutic effects were evaluated. We found that targeted therapy or chemotherapy did not significantly affect the T lymphocyte composition or circulating TCRB diversity (3.83 vs 3.74, T-test, p = .16) in patients with advanced lung adenocarcinoma (LUAD) during the first few treatment cycles. The higher circulating TCRB diversity was linked to improved therapeutic effects (T-test, p = .00083) in LUAD patients receiving targeted therapy. Higher baseline circulating TCRB diversity was associated with better prognosis. In addition, a five-factor prognostic risk score model was built for more accurate prognosis prediction for LUAD patients. The chemotherapeutic agents for advanced lung cancer do not significantly affect adaptive immune function over the first few treatment cycles. The circulating TCRB diversity reflects the adaptive immunological repertoire and might be a convenient indicator for evaluating the adaptive immune status and prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Oncoimmunology - 10(2021), 1 vom: 17. März, Seite 1899609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jiaqi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 02.08.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/2162402X.2021.1899609 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323519113 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323519113 | ||
| 003 | DE-627 | ||
| 005 | 20231226202825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/2162402X.2021.1899609 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1078.xml |
| 035 | |a (DE-627)NLM323519113 | ||
| 035 | |a (NLM)33796410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jiaqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic value of the baseline circulating T cell receptor β chain diversity in advanced lung cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 02.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. | ||
| 520 | |a An indicator for systemic evaluation of the adaptive immune status is lacking. Peripheral blood is important in antitumour immunity, and the T-cell receptor (TCR) repertoire diversity is key for effective immunity. This study aimed to investigate changes in the circulating T cell receptor β chain (TCRB) diversity during the first few (1 ~ 4) treatment cycles and its clinical value in patients with advanced lung cancer. TCRB-enriched sequencing data combined with transcriptomic RNA sequencing data of peripheral blood leukocytes were obtained from 72 patients with advanced lung cancer before and after targeted therapy or chemotherapy. Changes in the circulating TCRB diversity during treatment and the relationship of the baseline circulating TCRB diversity with prognosis and therapeutic effects were evaluated. We found that targeted therapy or chemotherapy did not significantly affect the T lymphocyte composition or circulating TCRB diversity (3.83 vs 3.74, T-test, p = .16) in patients with advanced lung adenocarcinoma (LUAD) during the first few treatment cycles. The higher circulating TCRB diversity was linked to improved therapeutic effects (T-test, p = .00083) in LUAD patients receiving targeted therapy. Higher baseline circulating TCRB diversity was associated with better prognosis. In addition, a five-factor prognostic risk score model was built for more accurate prognosis prediction for LUAD patients. The chemotherapeutic agents for advanced lung cancer do not significantly affect adaptive immune function over the first few treatment cycles. The circulating TCRB diversity reflects the adaptive immunological repertoire and might be a convenient indicator for evaluating the adaptive immune status and prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a T cell receptor repertoire | |
| 650 | 4 | |a advanced lung cancer | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a shannon-weiner index | |
| 650 | 4 | |a therapeutic effect | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell, alpha-beta |2 NLM | |
| 700 | 1 | |a Bie, Zhixin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yajing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yujie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Nie, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Di, Xuebing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaoguang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Shujun |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Lin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncoimmunology |d 2012 |g 10(2021), 1 vom: 17. März, Seite 1899609 |w (DE-627)NLM218817029 |x 2162-402X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g day:17 |g month:03 |g pages:1899609 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/2162402X.2021.1899609 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 1 |b 17 |c 03 |h 1899609 | ||